Get Premium to unlock powerful stock data
Redhill Biopharma Ltd logo

Redhill Biopharma Ltd

$ 1.03 -0.02 (-1.9%) 08:08 PM EST
P/E:
N/A
P/B:
27.94
Market Cap:
$ 54.86M
Enterprise V:
$ 105.73M
Volume:
322.73K
Avg Vol (2M):
418.65K
Also Trade In:
Volume:
322.73K
Market Cap $:
54.86M
PE Ratio:
N/A
Avg Vol (2-Month):
418.65K
Enterprise Value $:
105.73M
PB Ratio:
27.94
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 0.43
Equity-to-Asset 0.05
Debt-to-Equity 9.89
Debt-to-EBITDA -1.39
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.92
Distress
Grey
Safe
Beneish M-Score -3.27
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 31.77
9-Day RSI 27.41
14-Day RSI 27.99
6-1 Month Momentum % -24.38
12-1 Month Momentum % -69.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.09
Quick Ratio 0.91
Cash Ratio 0.47
Days Inventory 77.55
Days Sales Outstanding 122.38
Days Payable 86.15

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.7

Financials (Next Earnings Date:2022-05-27 Est.)

RDHL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:RDHL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 85.757
EPS (TTM) ($) -2.1
Beta 1.46
Volatility % 100.82
14-Day RSI 27.99
14-Day ATR ($) 0.150652
20-Day SMA ($) 1.365505
12-1 Month Momentum % -69.16
52-Week Range ($) 0.9 - 11.18
Shares Outstanding (Mil) 53.26

Piotroski F-Score Details

Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Redhill Biopharma Ltd Filings

Document Form Filing Date
No Filing Data

Headlines

See More